This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01163/identifier/pharmgkb/
n15http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB01163/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01163/identifier/drugbank/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01163/identifier/chebi/

Statements

Subject Item
n2:DB01163
rdf:type
n3:Drug
n3:description
Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.
n3:generalReferences
# Neu HC: Penicillin-binding proteins and role of amdinocillin in causing bacterial cell death. Am J Med. 1983 Aug 29;75(2A):9-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6311012
n3:group
withdrawn
n3:halfLife
Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.
n3:indication
Used in the treatment of urinary tract infections caused by some strains of E. coli and klebsiella and enterobacter species. Used mainly against Gram negative organisms.
owl:sameAs
n9:DB01163 n15:DB01163
dcterms:title
Amdinocillin
adms:identifier
n11:D02888 n12:51208 n13:DB01163 n14:PA164754807
n3:mechanismOfAction
Amdinocillin is a stong and specific antagonist of Penicillin Binding Protein-2 (PBP 2). It is active against gram negative bacteria, preventing cell wall synthesis by inhibiting the activity of PBP2. PBP2 is a peptidoglycan elongation initiating enzyme. Peptidoglycan is a polymer of sugars and amino acids that is the main component of bacterial cell walls.
n3:synonym
Mecillinam Penicillin HX
n3:synthesisReference
U.S. Patent 3,957,764.
n6:hasConcept
n7:M0000876
n3:IUPAC-Name
n4:271B4C6C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4C72-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4C71-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4C6E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4C6F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4C70-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4C82-363D-11E5-9242-09173F13E4C5 n4:271B4C6A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4C84-363D-11E5-9242-09173F13E4C5 n4:271B4C68-363D-11E5-9242-09173F13E4C5 n4:271B4C6B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4C69-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4C78-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4C79-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4C73-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4C74-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4C76-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4C75-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4C77-363D-11E5-9242-09173F13E4C5
n3:absorption
Poorly absorbed if given orally.
n3:affectedOrganism
Staphylococcus saprophyticus Gram-negative Bacteria Proteus mirabilis Escherichia coli
n3:casRegistryNumber
32887-01-7
n3:category
n3:Bioavailability
n4:271B4C7E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4C80-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4C81-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4C83-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4C7D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4C7C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4C7F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4C6D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4C7A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4C7B-363D-11E5-9242-09173F13E4C5